Pharvaris’ Post

Zai Lab has initiated a global Phase 2 clinical trial for #ZL1102, a #topicaltreatment targeting mild-to-moderate chronic #plaquepsoriasis. This novel therapy, known as #Humabody, aims to reduce systemic exposure and associated risks by applying directly to lesions. Early results show promising improvements in #psoriasis severity, potentially offering a safer, more effective treatment option for patients. https://lnkd.in/dqdvkeBX

In case you missed it Get an update on emerging therapies based on protein degradation and immunomodulation for relapsed/refractory multiple myeloma, including the latest data and ongoing clinical trials. Learn more with Prof. Cristina Gasparetto, Prof. Sagar Lonial and Prof. Sundar Jagannath: https://lnkd.in/emK-FWH2 This activity is funded by an independent medical education grant from Bristol Myers Squibb. This activity is jointly provided by USF Health and touchIME. #MultipleMyeloma #Immunomodulation #Myeloma #ClinicalTrials #Therapies #RRMM

Fascinating clinical application of this biomarker. A large prospective clinical trial could help determine future use of this predictive tool to identify population in ESKD at risk for future AVF failure #hemodialysis #dialysisaccess #esrd #eskd #avf #LGI #dialysisaccesspatency

A recent study by Truveta Research, in collaboration with Dr Ezekiel Emanuel from the University of Pennsylvania Perelman School of Medicine, has uncovered insights into the patterns of discontinuation and reinitiation of #GLP1 receptor agonists. Read at The Evidence Base® #outcomesresearch #rwe #rwd #realworldevidence #realworlddata #marketaccess #medicalaffairs #healthdata #healthequity

An article published in Pancreatology by Somashekar Krishna, a key clinical investigator for our mucinous pancreatic cyst clinical trial, reports further insights from a follow-on expanded access protocol he led of intracystic LSAM-PTX in pts with nonoperable high-risk BD-IPMNs. https://lnkd.in/gQSjCs-E

For those who may have missed it, Dr. David Wirta's article, "The Coming of Age for Dry Eye Disease," provides a comprehensive year-in-review snapshot of the significant progress in Dry Eye Disease (DED) development throughout 2023 and highlights some of Ora's technologies that contributed to this progress.   From insights into FDA-approved therapies to milestone clinical trials, the article emphasizes the role of novel technologies in advancing DED drug development. Whether leveraging remote research solutions, like the Ora EyeCup platform, or decentralized challenge chambers, such as the Ora Controlled Adverse Environment (CAE), 2023 has shown that novel technology and strategies are essential for accessing and enriching global DED patient populations. Explore the full article below to delve into the novel therapies, technologies, and strategies employed in 2023 and beyond! #dryeyedisease #clinicalresearch #ophthalmology

Excited to share my recently published research! Imagine living every day knowing your red blood cells could be destroyed at any moment. This is the reality for patients with Paroxysmal Nocturnal Hemoglobinuria (PNH), a rare and life-threatening blood disorder caused by uncontrolled hemolysis. My research, titled "Iptacopan Efficacy and Safety to Treat Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Meta-Analysis" , explores the potential of Iptacopan as a groundbreaking treatment. By targeting factor B and disrupting the complement pathway earlier, Iptacopan offers hope for better outcomes with the convenience of oral administration—unlike traditional intravenous therapies. Special thanks to Dr. Ibrahim M. Dighriri and my colleagues : • Reham M. Al-Qahtani • Amal O. Almutairi • Rahaf N. Alhashbari • Hanin A. Kanbeja • Salman A. AlOjaimi • Mona A. Aljuaid • Abdullah A. Albaradi • Sahar T. Almanjumi • Samah A. Alqurashi • Maryam S. Majrashi • Hatoon M. Alansari •Abdulaziz S. Alharbi • Amnah A. Alnami If you're interested in learning more, you can read the full study here: https://lnkd.in/e2bhwEsZ #PNH #Iptacopan #Research #Healthcare #Pharmacy #BloodDisorders #ClinicalPharmacy #MedicalResearch #PatientCare

Wow, so this is a thing! Finally some promising results of clinical trials with bacteriophages! Thank you for this amazing progress, BiomX Inc https://lnkd.in/dq_gd9FW Having statistically well evaluated results of the clinical trials is an essential step to persuade more not-so-involved people, that phage therapy works. Let's wait what happened after (hopefully successful) phase III. #phagetherapy #clinicaltrials #bacteriophages

Trial data analyzed using the #SteritasGTI has shown that sarilumab is effective in reducing #SteroidToxicity, with significant improvement to the cumulative worsening and aggregate improvement scores. 📈 Learn what this could mean for patients battling polymyalgia rheumatica: https://hubs.li/Q02bv1wF0 #Rheumatology #InflammatoryDisease #PatientCare